FGI-106

FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against Ebola, Rift Valley and Dengue Fever viruses with EC₅₀s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC₅₀s of 200 nM and 150 nM, respectively^[1]. IC50 & Target: EC50: 100 nM (Ebola virus), 800 nM (Rift Valley virus), 400-900 nM (Dengue Fever virus), 200 nM (HCV) and 150 nM (HIV-1)^[1] In Vitro: Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC₉₀ for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM^[1].
In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses^[1]. In Vivo: FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner^[1].